/Research Database
← Research Database
Sehr niedrigMensch2026

Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers.

Marc Pawlitzki, Patricia Kirschner, Lars Masanneck, Ramona Hagler et al.

Kernaussage

In multiple sclerosis patients, a higher brain age gap (BrainAGE) is associated with increased disability and disease duration, but is independent of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels.

Abstract

Multiple sclerosis (MS) is influenced by age-related brain alterations and affects cellular aging mechanisms. Machine-learning models can estimate brain-predicted age from magnetic resonance imaging (MRI) to quantify these aging-related changes. This study examines whether the difference between predicted and chronological age (BrainAGE) relates to clinical disability and biomarkers of neuro-axonal injury in MS. This study analyzed brain-predicted age from structural 3D T1-weighted MRI in 82 patients with relapsing MS enrolled in three prospective clinical trials and 30 healthy controls. BrainAGE, calculated as MRI-predicted minus chronological age, was correlated with the Expanded Disability Status Scale (EDSS), MS Functional Composite subtests, and serum neurofilament light chain and glial fibrillary acidic protein. The mean chronological age of patients and healthy controls included in this study was 39.2 and 40.9 years, respectively. Patients with MS ( n = 82) showed a higher BrainAGE (6.48 ± 6.83 years) than controls ( n = 30; 0.69 ± 6.5 years; p = 0.0002). BrainAGE increased stepwise from controls to patients with EDSS < 3 and EDSS ⩾3 ( p < 0.0001). Higher BrainAGE correlated with worse 9-Hole Peg Test (9HPT, ρ = 0.34, p = 0.002) and Timed 25-Foot Walk performance (T25FW, ρ = 0.23, p = 0.043), but not with serum neurofilament light chain ( p = 0.68) or glial fibrillary acidic protein ( p = 0.33). In multivariable regression models adjusting for chronological age, sex, disease duration, and disease-modifying therapy, BrainAGE remained significantly associated with EDSS, 9HPT, and T25FW performance. sNfL and sGFAP remained nonsignificant after adjustment. Our findings suggest that BrainAGE and serum biomarkers capture complementary aspects of MS pathology, supporting a multimodal approach to assess disease progression. ClinicalTrials.gov ID: SATURATE: NCT05701423, 360PMS: NCT06501950, SAFEGUIDE-MS: NCT06461481.

Kein medizinischer Rat. Die dargestellten Studien dienen der wissenschaftlichen Information und ersetzen keine ärztliche Beratung. Bei gesundheitlichen Fragen wende dich an eine approbierte Ärztin oder einen Arzt.

Quelle: PubMed Central / National Library of Medicine (NLM). Apollion steht in keiner Verbindung mit NLM und wird von NLM nicht empfohlen. Evidenzgrade bewerten die methodische Studienqualität — nicht die inhaltliche Richtigkeit.

Lizenz: CC BY — Inhalte werden ausschließlich aus Open-Access-Quellen mit kommerziell nutzbaren Lizenzen (CC0, CC BY, CC BY-SA) indexiert.